Thermo Fisher Scientific (NYSE:TMO) Stock Gets Price Target Boost from TD Cowen

Posted by Francis Steltz on Oct 22nd, 2026

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) had its price target boosted by research analysts at TD Cowen from $760.00 to $810.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. TD Cowen’s target price would suggest a potential upside of 18.21% from the stock’s current price.

A number of other equities research analysts also recently weighed in on the company. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Citigroup lowered Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research report on Wednesday, September 9th. Royal Bank Of Canada reissued a “sector perform” rating on shares of Thermo Fisher Scientific in a report on Thursday. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $720.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $672.67.

Get Our Latest Stock Analysis on TMO

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded down $8.82 on Thursday, hitting $685.20. 663,180 shares of the company traded hands, compared to its average volume of 2,262,024. The firm’s 50-day simple moving average is $642.42 and its 200 day simple moving average is $552.67. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The company has a market cap of $253.35 billion, a P/E ratio of 36.76, a P/E/G ratio of 2.87 and a beta of 0.87. Thermo Fisher Scientific has a 12-month low of $435.27 and a 12-month high of $705.78.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same period in the previous year, the firm posted $5.79 EPS. The firm’s revenue was up 9.1% compared to the same quarter last year. Analysts expect that Thermo Fisher Scientific will post 25.13 earnings per share for the current fiscal year.

Insider Activity

In other Thermo Fisher Scientific news, EVP Michael Shafer sold 25,500 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares of the company’s stock, valued at $12,596,400. This trade represents a 54.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc Casper sold 275 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at $77,707,171.25. The trade was a 0.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Strengthening Families & Communities LLC lifted its holdings in Thermo Fisher Scientific by 0.4% in the 3rd quarter. Strengthening Families & Communities LLC now owns 4,721 shares of the medical research company’s stock worth $3,187,000 after buying an additional 21 shares during the period. Bell Bank grew its position in shares of Thermo Fisher Scientific by 10.8% in the 3rd quarter. Bell Bank now owns 624 shares of the medical research company’s stock worth $421,000 after buying an additional 61 shares during the last quarter. 55 North Private Wealth LLC raised its holdings in shares of Thermo Fisher Scientific by 40.9% during the third quarter. 55 North Private Wealth LLC now owns 906 shares of the medical research company’s stock valued at $612,000 after acquiring an additional 263 shares in the last quarter. Jeppson Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific during the third quarter valued at approximately $213,000. Finally, James Hambro & Partners LLP lifted its stake in Thermo Fisher Scientific by 0.8% in the third quarter. James Hambro & Partners LLP now owns 231,390 shares of the medical research company’s stock worth $156,260,000 after acquiring an additional 1,919 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

Positive Sentiment: Quarterly results exceeded expectations: Q3 revenue rose 9.1% year over year to $12.14 billion, while adjusted EPS increased 15% to $6.68, beating consensus estimates of $11.95 billion and $6.40, respectively. Thermo Fisher Scientific Reports Third Quarter 2026 Results
Positive Sentiment: Growth broadened across key end markets: Organic revenue growth reached 6%, supported by pharmaceutical demand, clinical research, bioproduction and electron microscopy. Management also highlighted continued customer activity, AI integration and signs of recovery in previously weaker markets. TMO Q3 deep dive
Positive Sentiment: Profitability and outlook improved: Operating margin reached 24.5%, aided by portfolio actions and productivity initiatives. Thermo Fisher raised its full-year 2026 revenue and earnings outlook, including a 4% organic revenue-growth target. Three key takeaways
Positive Sentiment: Analyst confidence increased: Robert W. Baird raised its price target from $723 to $756 and upgraded or reaffirmed an “outperform” rating, implying additional upside from the current trading level.
Neutral Sentiment: Investors delivered a measured response: Despite the earnings beat and higher guidance, the stock’s reaction has been relatively restrained, suggesting that strong results may have been partly anticipated and that valuation remains an important consideration. Q3 earnings disconnect
Negative Sentiment: Short-term caution remains: Early trading included selling pressure following the report, and put-option purchases rose about 52% above average volume, indicating that some investors are hedging against volatility or disappointment after the earnings release.

About Thermo Fisher Scientific

(Get Free Report)

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.